SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on June 23, 2014. The report discloses a corporate governance update pursuant to Regulation FD (Item 7.01). The filing announces the appointment of Dr. C. Ronald Kahn to the Company's Scientific Advisory Board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the addition of Dr. C. Ronald Kahn to the Scientific Advisory Board. No financial or operational changes compared to prior periods are detailed in this document.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies are discussed beyond the standard regulatory language stating that the information is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Dr. C. Ronald Kahn has been appointed to the Scientific Advisory Board.
- The announcement was made via a press release dated June 23, 2014 (Exhibit 99.1).
- The information is furnished under Regulation FD and is not deemed "filed" for liability purposes under the Exchange Act.
- The filing contains no financial data; investors should refer to the most recent 10-K or 10-Q for financial status.